Holen Sie sich die Stockscreener-App
3.465
16.71%
-0.695
Handel nachbörslich:
3.49
0.025
+0.72%
Schlusskurs vom Vortag:
$4.16
Offen:
$4.11
24-Stunden-Volumen:
40.50M
Relative Volume:
0.98
Marktkapitalisierung:
$1.86B
Einnahmen:
$66.41M
Nettoeinkommen (Verlust:
$-559.78M
KGV:
-2.8822
EPS:
-1.2022
Netto-Cashflow:
$-328.09M
1W Leistung:
-20.53%
1M Leistung:
+8.62%
6M Leistung:
-3.75%
1J Leistung:
-45.52%
1-Tages-Spanne:
$3.44
$4.185
1-Wochen-Bereich:
$3.44
$4.41
52-Wochen-Spanne:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.465 | 1.86B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com South Africa
Director Hershberg sells $125k in Recursion Pharmaceuticals stock - Investing.com
Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com UK
Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. - Stock Titan
A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). - Stock Titan
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Recursion Pharmaceuticals Director Hershberg to Sell 25,000 Shares via Option Exercise - Kalkine Media
Recursion Pharmaceuticals, Inc.Class A Common Stock (Nasdaq:RXRX) Stock Quote - FinancialContent
A $0-per-share award brings Zavain Dar's direct Recursion (RXRX) holdings to 245,371 shares. - Stock Titan
Dean Y. Li receives 3,378 Recursion (RXRX) shares under its Outside Director Compensation Policy. - Stock Titan
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - Investing.com
Recursion Pharma CEO Najat Khan sells $78,822 in stock - Investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Quiver Quantitative
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - Eastern Progress
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Canada
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
Recursion (NASDAQ: RXRX) director sells 30,000 shares in planned trade - Stock Titan
RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn - StocksToTrade
RXRX | Recursion Pharmaceuticals, Inc. Class FinancialsRevenue Breakdown - Quiver Quantitative
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Ex-Recursion (NASDAQ: RXRX) director plans new sale after 340K-share June trade - Stock Titan
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Recursion Pharmaceuticals Inc-Aktie (RXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Oct 06 '26 |
Proposed Sale |
4.84 |
50,000 |
242,000 |
0 |
| HERSHBERG ROBERT | Director |
Oct 06 '26 |
Proposed Sale |
5.00 |
25,000 |
125,000 |
0 |
| HERSHBERG ROBERT | Director |
Oct 06 '26 |
Option Exercise |
2.22 |
25,000 |
55,500 |
187,156 |
| HERSHBERG ROBERT | Director |
Oct 06 '26 |
Sale |
5.00 |
25,000 |
125,000 |
162,156 |
| Najat Khan | Officer |
Sep 08 '26 |
Proposed Sale |
3.52 |
22,408 |
78,822 |
0 |
| Khan Najat | CEO and President |
Sep 08 '26 |
Sale |
3.52 |
22,408 |
78,822 |
2,072,890 |
| Borgeson Blake | Director |
Sep 01 '26 |
Proposed Sale |
3.34 |
30,000 |
100,200 |
0 |
| Borgeson Blake | Director |
Sep 01 '26 |
Sale |
3.34 |
30,000 |
100,200 |
6,158,287 |
| Gibson Christopher | Former Director |
Aug 21 '26 |
Proposed Sale |
3.39 |
77,290 |
262,013 |
0 |
| Gibson Christopher | Former Director |
Aug 20 '26 |
Proposed Sale |
3.40 |
75,000 |
255,000 |
0 |
3.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):